Carmel, IN. - ParaPRO LLC, a specialty pharmaceutical company, announced today that the company has created a permanent technology advisory board to help the company plan for and develop a compound for the treatment of head lice.
The board consists of experts in the field of head lice research and treatment and will provide guidance on technical and business issues. The group will meet on an ongoing basis to review market research, receive updates on the regulatory and clinical trial process and provide input to company management on business strategy and tactics.
Dr. John Clark from the MA Pesticide Analysis Laboratory and a coordinator of the Human Lice Genome Project at UMASS and Dr. Richard Pollack from the Laboratory of Public Health Entomology at Harvard School of Public Health have a wealth of experience with the anatomy of the head louse, methods of treating lice infestations and the resistance of lice to various compounds in areas around the world. They will be joined by Dr. Judy Knight from the American Academy of Pediatrics, Annette Marette from the Indiana State School Nurse Association and Charlene Morris from the Association of Family Practice Physician Assistants. Additional members will be added in the future as needs develop.
Natrova™ is the proposed name for the investigational product to treat human head lice. If the product is approved by the FDA, ParaPRO anticipates that NatrOVA would be the first new product to be approved in over 20 years for the treatment of human head lice. The product has completed phase 2 clinical trials. It is expected that phase 3 trials will begin in the fall of 2007.
ParaPRO LLC was founded in 2002 when SePRO Corporation of Carmel, IN purchased the worldwide rights to develop and market Spinosad for the control of lice in human health from Eli Lilly and Company. The compound is currently in clinical trials at multiple sites across the United States. More information on ParaPRO can be found at www.parapro.com.
SePRO Corporation is recognized as an industry leader in providing the highest level of technical service to customers who operate in specialty markets of the USA. To learn more about SePRO Corporation, its products, services and technologies, call 1-800-419-7779 or visit the SePRO web site at www.sepro.com.
Ask your doctor if Natroba™ Topical Suspension is right for you or your child.
Natroba™ Topical Suspension is a pediculicide indicated for the topical treatment of head lice infestations in patients
six (6) months of age and older.
Natroba™ Topical Suspension should be used in the context of an overall lice management program:
- Wash (in hot water) or dry clean all recently worn clothing, hats, used bedding and towels
- Wash personal care items such as combs, brushes, and hair clips in hot water
A fine-toothed comb or special nit comb may be used to remove dead lice and nits.
IMPORTANT SAFETY INFORMATION
Natroba™ Topical Suspension contains benzyl alcohol and is not recommended for use in neonates and infants below the age of 6 months.
Systemic exposure to benzyl alcohol has been associated with serious adverse reactions and death in neonates
and low birth-weight infants. Most common adverse events were: application site redness (3%), eye redness (2%) and application
site irritation (1%).
Consult the Patient Information, Full Prescribing Information and your doctor for more complete information on Natroba™ Topical Suspension.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.